No Racial Differences in DLBCL Treatment Within VA Healthcare System
No statistically significant racial differences in diffuse large B-cell lymphoma (DLBCL) outcomes were found for patients treated within the VHA, according to recent research.
No statistically significant racial differences in diffuse large B-cell lymphoma (DLBCL) outcomes were found for patients treated within the VHA, according to recent research.
Diffuse large B-cell lymphoma (DLBCL) becomes much more difficult to treat in older patients, according to a new study suggesting that more adults of advanced age be included in clinical trials for new agents.
Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or progress following first-line chemoimmunotherapy.
Individuals who have served in the U.S. military have about three times the risk of monoclonal gammopathy of undetermined significance (MGUS) as a similarly aged cohort in the Icelandic iStopMM study.